Market Share in Infectious Disease Molecular Testing

  • Published on
    14-Apr-2017

  • View
    16

  • Download
    8

Transcript

Market Share in Infectious Disease Molecular Testing Infectious disease is a key area to watch in molecular, though it has many applications. This brief White Paper reviews the market share picture for molecular testing. It is based on Kalorama Informations 7th Edition of its World Market for Molecular Diagnostics report. There is little gray area in terms of undetermined market share in molecular infectious disease diagnostics. Eight companies are estimated to account for 86% of the global market (Figure accompanying). Roche Diagnostics has been an unmovable leader with a market share estimated at 21%. The companys resources and history in the market have allowed it to adapt and diversify as needed, most recently with its Liat system for CLIA-waived molecular infectious disease testing, HPV assay FDA-approved for primary screening, and new viral load assays for its cobas 6800/8800 core lab virology systems. Hologic claims a large market share through its leadership in the molecular CT/NG and HPV testing space. Cepheid and bioMrieux have significantly increased market share in molecular infectious disease diagnostics over the past few years through respective placements of GeneXpert and FilmArray systems in hospital labs. The success of Cepheid and bioMrieux validates the development efforts of competitors in the same space of decentralized molecular testing. Remaining market leaders Becton, Dickinson & Co. (BD), Abbott Diagnostics, Siemens Healthcare Diagnostics have been markedly less dynamic in molecular infectious disease testing, though BD has been active in more fully addressing its markets in HAI and womens health/sexual health. Abbott and Siemens have stuck more to core molecular infectious disease markets in virology (HIV/hepatitis). Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices. The primary technologies for clinical molecular diagnostics include nucleic acid amplification tests (NAATs) based on real-time PCR (qPCR) and other amplification-detection protocols; direct nucleic acid probe tests such as in situ hybridization (ISH) and its fluorescent ISH (FISH); next-generation sequencing (NGS); amplification followed by probe-based hybridization on arrays (or microarrays); and other related methods. The market for infectious disease diagnostics was traditionally dominated by virology or HIV and hepatitis testing including infection diagnosis, virus genotyping, and viral load testing. Together, HIV and hepatitis still represent roughly 40% of the entire molecular diagnostics market in infectious diseases. Hospital-acquired infections and bloodstream infections now represent the largest market segment due to the threat of antimicrobial resistance (AMR) in hospitals and rising complexity of testing deployed in cases of inpatient infections. Molecular assays have been highly successful in hospital markets due to their unique ability to identify the infection and characterize resistance within actionable timelines. N O W P U B L I S H E D The World Market for Molecular Diagnostics 7th Edition http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/ Molecular tests have become routine and expanded to all levels of healthcare from the pathology lab all the way to the doctors office and clinics of the developing world. Molecular diagnostics now represents more than one-tenth of the global IVD market with a growth trajectory secured through platform innovation in lower-cost nucleic acid amplification tests (NAATs) and clinical next-generation sequencing (NGS). Kalorama Information has now published its 7th edition of The World Market for Molecular Diagnostics. This comprehensive report provides detailed information on relevant test kits, other reagents and instruments that are used for clinical testing. Market data is provided, products on the market detailed and trends discussed. While not matching its explosive market growth in years past, clinical molecular diagnostics has delivered on its promise in health care. Kalorama Information analyst Emil Salazar details the status of the molecular diagnostics market, as it stands in 2017. The major applications of clinical molecular diagnostics include the following, and are covered in the report: Infectious disease diagnostics - molecular microbiology and virology, including the detection, identification, quantification and nucleic-acid based resistance or susceptibility profiling of pathogens. Blood transfusion diagnostics - nucleic acid screening (NAT) of donated blood, often pooled samples, for the detection of active infections responsible for transfusion transmitted infections Molecular diagnostics is demonstrating revenue growth at more than twice the rest of the IVD market While not matching its explosive market growth in years past, clinical molecular diagnostics has delivered on its promise in healthcare -Emil Salazar, IVD Analyst and Author Detailed Market Intelligence in All Segments of Molecular Testing - Based on Real Company Events and Intelligence http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/ Histology / cytology diagnostics - largely synonymous with in situ hybridization (ISH) methods that use direct hybridization of chromogenic (CISH) or fluorescent (FISH) nucleic acid probes within slided tissue or suspended cell samples viewed under microscopy. Cancer diagnostics - tissue, blood and urine samples can be assayed using nucleic acid amplification tests (NAATs) or sequencing to diagnose, prognose and identify key mutations for targeted therapies; future additional capabilities are premised on liquid biopsy sampling (non-invasive fluid samples such as venous blood or urine) and next-generation sequencing (NGS). Transplant diagnostics - various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients. Inherited disease diagnostics - diagnosis of rare genetic diseases and other inherited traits. Once esoteric, molecular tests have become routine and expanded to all levels of healthcare from the pathology lab all the way to the doctors office and clinics of the developing world. Kalorama Information analyst Emil Salazar details the status of the molecular diagnostics market, as it stands in 2017. Detailed Market Analysis As part of its coverage, the following is included:: Molecular Diagnostics for Infectious Disease Market, 2016-2021 Molecular Diagnostics for Cancer Market 2016-2021 Molecular Diagnostics for NAT Blood Screening Market 2016-2012 Molecular Diagnostics for Hepatitis Market HIV Molecular Diagnostics Market, 2016 to 2021 HAIs/Sepsis Molecular Diagnostics Market, 2016 to 2021 CT/NG Molecular Diagnostics Market, 2016 to 2021 HPV Molecular Diagnostics Market, 2016 to 2021 Respiratory Molecular Diagnostics Market, 2016 to 2021 Mycobacteria/TB Molecular Diagnostics Market, 2016 to 2021 Other Infectious Disease Molecular Diagnostics Market, 2016 to 2021 in situ hybridization (ISH) Market by Application (Genetic Disorders, Cancer, Infectious and Other) 2016 to 2021 Other Histology Molecular Diagnostics Market, 2016 to 2021 Inherited Diseases Molecular Diagnostics Market, 2016 to 2021 Transplant Diagnostics Molecular Diagnostics Market, 2016 to 2021 Kaloramas Report Contains Superior Graphics Designed to Clearly Explain Changes in the Market Market Share and Global Segmentation There are a great number of companies participating in these segments of molecular diagnostics, from molecular specialists to the top-tier IVD companies. This report offers superior detail, identifying market share not only for the overall molecular diagnostics market but for molecular test categories, including: Molecular Blood Testing Market Share Analysis Molecular Cancer Testing Market Share Analysis Molecular Transplantation Market Share Analysis Molecular Infectious Disease Market Share Analysis Inherited Disease Testing Market Share Analysis The segmented market share allows competitors and interested market-watchers to see not only how a company is performing in the overall molecular diagnostics market, but also in their specialty area. To assist in global business planning efforts, this report contains market estimates for major world regions including the United States, Europe, Japan, China and Latin America. Data in the report includes: Regional Markets for Molecular Blood Screening Geographic Market Segmentation ( United States, Europe, Japan, China, Latin America, Rest of World) Regional Markets for Molecular Cancer Testing Market Share ( United States, Europe, Japan, China, Latin America, Rest of World) Regional Markets for Molecular Transplantation Market Share ( United States, Europe, Japan, China, Latin America, Rest of World) Regional Markets for Molecular Infectious Disease Market Share ( United States, Europe, Japan, China, Latin America, Rest of World) Regional Markets for Inherited Disease Testing Market Share ( United States, Europe, Japan, China, Latin America, Rest of World) Superior Company Profiling This report contains profiles of major companies competing in molecular diagnostics. For each company, revenues, market share, products on the market and acquisitions and other deals are detailed. The following companies are profiled in the report: Abbott Diagnostics Advanced Cell Diagnostics Affymetrix (Thermo Fisher Scientific) Agilent Technologies Alere Amoy Diagnostics Applied Spectral Imaging Beckman Coulter (Danaher) Becton, Dickinson & Co. (BD) Beijing Genomics Institute (BGI) Berry Genomics Biocartis bioMrieux Bio-Rad Laboratories Cepheid (Danaher) Covaris Dako (Agilent Technologies) Eiken Chemical Epigenomics Exosome Diagnostics Genmark Diagnostics Grifols Immucor Janssen Diagnostics (Johnson & Johnson) Leica Biosystems (Danaher) Luminex Corporation Meridian Bioscience Nanosphere (Luminex) Nanostring Technologies Qiagen Quidel Roche Diagnostics Siemens Healthcare Diagnostics Thermo Fisher Scientific Others FOR MORE INFORMATION, OR TO ORDER: http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/ http://www.kaloramainformation.com/Molecular-Diagnostics-Edition-10595682/